Luca Degli Esposti1, Anna Girardi2, Stefania Saragoni2, Stefania Sella3, Margherita Andretta4, Maurizio Rossini5, Sandro Giannini3. 1. CliCon S.r.l. Health, Economics & Outcomes Research, Ravenna, Italy. luca.degliesposti@clicon.it. 2. CliCon S.r.l. Health, Economics & Outcomes Research, Ravenna, Italy. 3. Department of Medicine, Clinica Medica 1, University of Padova and Regional Center for Osteoporosis, Padova, Italy. 4. UOC HTA, Azienda Zero-Regione Veneto, Verona, Italy. 5. Rheumatology Unit, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy.
Abstract
PURPOSE: To evaluate the impact of pharmacological treatment in osteoporosis patients with recent fracture and to assess the incidence of subsequent fracture and all-cause mortality. METHODS: This observational retrospective study was based on data from administrative databases of five Italian Local Health Units. Osteoporosis patients aged ≥ 50 years with hospitalization for vertebral or hip fracture occurring between 01/01/2011 and 31/12/2015 were included. Treatment adherence was calculated using the medication possession ratio. Multivariable proportional hazard Cox model was used to identify factors associated with time to re-fracture and all-cause mortality. RESULTS: A cohort of 3475 patients were included and 41.5% of them did not receive any specific anti-fracture treatment. Among treated patients (N = 2032), the majority (83.6%) received calcium/vitamin D supplementation. Over a mean follow-up of 3 years, the risk of subsequent fractures was 44.4% lower in treated patients compared to untreated ones (HR = 0.556, 95% CI = 0.420-0.735, p < 0.001) and 64.4% lower in those receiving calcium/vitamin D supplementation compared to osteoporosis treatment only (HR = 0.356, 95% CI = 0.237-0.533, p < 0.001). The risk of re-fracture was 77.2% lower in treated patients who were adherent to medication (HR = 0.228, 95% CI = 0.139-0.376, p < 0.001). Treated patients had 64% lower mortality risk over the follow-up compared to untreated ones (HR = 0.360, 95% CI = 0.310-0.418, p < 0.001). CONCLUSIONS: A consistent proportion of osteoporosis patients did not receive specific treatment after a fracture, showing poor adherence to national guidelines on osteoporosis treatment. Osteoporosis drug treatment, and to a greater extent in combination with calcium/vitamin D, and adherence were correlated with lower risk of both re-fracture and all-cause mortality.
PURPOSE: To evaluate the impact of pharmacological treatment in osteoporosispatients with recent fracture and to assess the incidence of subsequent fracture and all-cause mortality. METHODS: This observational retrospective study was based on data from administrative databases of five Italian Local Health Units. Osteoporosispatients aged ≥ 50 years with hospitalization for vertebral or hip fracture occurring between 01/01/2011 and 31/12/2015 were included. Treatment adherence was calculated using the medication possession ratio. Multivariable proportional hazard Cox model was used to identify factors associated with time to re-fracture and all-cause mortality. RESULTS: A cohort of 3475 patients were included and 41.5% of them did not receive any specific anti-fracture treatment. Among treated patients (N = 2032), the majority (83.6%) received calcium/vitamin D supplementation. Over a mean follow-up of 3 years, the risk of subsequent fractures was 44.4% lower in treated patients compared to untreated ones (HR = 0.556, 95% CI = 0.420-0.735, p < 0.001) and 64.4% lower in those receiving calcium/vitamin D supplementation compared to osteoporosis treatment only (HR = 0.356, 95% CI = 0.237-0.533, p < 0.001). The risk of re-fracture was 77.2% lower in treated patients who were adherent to medication (HR = 0.228, 95% CI = 0.139-0.376, p < 0.001). Treated patients had 64% lower mortality risk over the follow-up compared to untreated ones (HR = 0.360, 95% CI = 0.310-0.418, p < 0.001). CONCLUSIONS: A consistent proportion of osteoporosispatients did not receive specific treatment after a fracture, showing poor adherence to national guidelines on osteoporosis treatment. Osteoporosis drug treatment, and to a greater extent in combination with calcium/vitamin D, and adherence were correlated with lower risk of both re-fracture and all-cause mortality.
Authors: C Cipriani; J Pepe; F Bertoldo; G Bianchi; F P Cantatore; A Corrado; M Di Stefano; B Frediani; D Gatti; A Giustina; T Porcelli; G Isaia; M Rossini; L Nieddu; S Minisola; G Girasole; M Pedrazzoni Journal: J Endocrinol Invest Date: 2017-09-27 Impact factor: 4.256
Authors: Rachel Halpern; Laura Becker; Sheikh Usman Iqbal; Lewis E Kazis; David Macarios; Enkhjargal Badamgarav Journal: J Manag Care Pharm Date: 2011 Jan-Feb
Authors: Steven R Cummings; Javier San Martin; Michael R McClung; Ethel S Siris; Richard Eastell; Ian R Reid; Pierre Delmas; Holly B Zoog; Matt Austin; Andrea Wang; Stepan Kutilek; Silvano Adami; Jose Zanchetta; Cesar Libanati; Suresh Siddhanti; Claus Christiansen Journal: N Engl J Med Date: 2009-08-11 Impact factor: 91.245
Authors: S Adami; S Giannini; G Bianchi; L Sinigaglia; O Di Munno; C E Fiore; S Minisola; M Rossini Journal: Osteoporos Int Date: 2008-06-13 Impact factor: 4.507
Authors: Stefano Frara; Marco Losa; Mauro Doga; Anna Maria Formenti; Pietro Mortini; Gherardo Mazziotti; Andrea Giustina Journal: J Endocr Soc Date: 2018-07-27
Authors: D González-Quevedo; D Bautista-Enrique; V Pérez-Del-Río; M Bravo-Bardají; D García-de-Quevedo; I Tamimi Journal: Osteoporos Int Date: 2019-09-11 Impact factor: 4.507
Authors: T Chevalley; M L Brandi; E Cavalier; N C Harvey; G Iolascon; C Cooper; D Hannouche; J-F Kaux; A Kurth; S Maggi; G Maier; K Papavasiliou; N Al-Daghri; M Sosa-Henríquez; N Suhm; U Tarantino; J-Y Reginster; R Rizzoli Journal: Osteoporos Int Date: 2021-05-20 Impact factor: 4.507
Authors: C Muschitz; M Hummer; J Grillari; A Hlava; A H Birner; M Hemetsberger; H P Dimai Journal: Osteoporos Int Date: 2021-10-08 Impact factor: 4.507
Authors: Umberto Tarantino; Ida Cariati; Virginia Tancredi; Donato Casamassima; Eleonora Piccirilli; Riccardo Iundusi; Elena Gasbarra Journal: Int J Environ Res Public Health Date: 2020-10-22 Impact factor: 3.390
Authors: John P Bilezikian; Daniel Bikle; Martin Hewison; Marise Lazaretti-Castro; Anna Maria Formenti; Aakriti Gupta; Mahesh V Madhavan; Nandini Nair; Varta Babalyan; Nicholas Hutchings; Nicola Napoli; Domenico Accili; Neil Binkley; Donald W Landry; Andrea Giustina Journal: Eur J Endocrinol Date: 2020-11 Impact factor: 6.558